Andera Partners’ specialist therapeutics and medical technologies asset management company, Andera Life Sciences, closed its BioDiscovery 6 fund with €456 million in capital commitments.
Existing institutional investors of the BioDiscovery funds have chosen to support the new vehicle along with new subscribers, including funds of funds, insurance companies, pension funds, family offices, private investors and pharmaceutical companies.
The new fund will enable the management team to pursue its investment strategy focused on building a balanced portfolio of innovative companies developing therapeutics and medical technologies, at all stages of their development, in Europe and the United States. To date, BioDiscovery 6 has made six investments in Evommune, Amolyt, TargED, Tubulis, Mineralys and Imcheck.
Since its inception, the BioDiscovery fund family has raised over € 1.1 billion euros and the team has invested in over eighty European and North American therapeutics and medical technology companies, thereby becoming a benchmark in investment dedicated to life sciences. The BioDiscovery funds have generated over forty remarkable exits, including around twenty companies sold, such as Corvidia, Arvelle, Sanifit and ReViral, and around twenty initial public offerings, such as Axonics, Nyxoah and LogicBio.
